Restoration of frontal activation during a treatment with quetiapine: an fMRI study of blunted affect in schizophrenia

Stip, Émmanuel; Fahim, Chérine; Mancini-Marı̈e, Adham; Bentaleb, Lahcen Aït; Mensour, Boualem; Mendrek, Adrianna; Beauregard, Mario

doi:10.1016/j.pnpbp.2004.08.015

Cited by 48 publications

(38 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Quetiapine significantly increased PFC activation during an emotional processing task (Stip et al 2005). Untreated schizophrenic patients showed significant hypoactivation in the dorsolateral and ventrolateral PFC during a working memory task (Meisenzahl et al 2006); quetiapine treatment for 12 weeks significantly increased BOLD activity in the PFC during the task.…”

Section: Magnetic Resonance Imaging Studiesmentioning

confidence: 93%

Regional Differences in the Action of Antipsychotic Drugs: Implications for Cognitive Effects in Schizophrenic Patients

et al. 2010

View full text Add to dashboard Cite

Antipsychotic drugs (APDs) have been classified as typical or atypical based on their liability to produce extrapyramidal side effects: atypical APDs are less likely to produce extrapyamidal side effects at therapeutic doses. Evidence from immediate early gene immunohistochemical, electrophysiological, microdialysis, imaging, and behavioral studies suggests that typical APDs preferentially affect the nucleus accumbens (NAc) and the dorsal striatum while atypical APDs preferentially affect the NAc and medial prefrontal cortex (PFC). We review some of this evidence and then discuss studies that have employed cognitive tasks shown previously to depend on dorsal striatal or medial PFC function in schizophrenic patients treated with typical or atypical APDs. Results revealed that patients treated with typical APDs displayed deficits in cognitive tasks that depended on the dorsal striatum but not in tasks that depended on the medial PFC and that those treated with atypical APDs displayed deficits in cognitive tasks that depended on the medial PFC but not in cognitive tasks that depended on the dorsal striatum. These findings suggest that some of the cognitive deficits seen in schizophrenic patients may be related to the medications that are used to treat them.

show abstract

Section: Magnetic Resonance Imaging Studiesmentioning

confidence: 93%

Regional Differences in the Action of Antipsychotic Drugs: Implications for Cognitive Effects in Schizophrenic Patients

et al. 2010

View full text Add to dashboard Cite

show abstract

“…In a recent preliminary open trial (Stip et al, 2004), quetiapine significantly improved the negative symptoms of blunted affect in patients with schizophrenia; functional magnetic resonance imaging showed that frontal activation was restored in these patients following quetiapine treatment (previous studies having shown a lack of frontal activation in patients with blunted affect).…”

Section: Discussionmentioning

confidence: 91%

Quetiapine versus olanzapine for the treatment of negative symptoms in patients with schizophrenia

Sirota

Pannet

Koren

et al. 2006

Human Psychopharmacology

View full text Add to dashboard Cite

Negative symptoms are considered the most debilitating and refractory aspect of schizophrenia, being associated with poor social, occupational and global outcomes. Conventional antipsychotics have limited efficacy against these symptoms and poor tolerability profiles. Atypical antipsychotics are an alternative treatment, and this 12-week, randomised, flexibly dosed study compared the efficacy, safety and tolerability of quetiapine and olanzapine in this regard. Of the 40 patients who entered the study (32 male; 8 female), 19 were randomised to quetiapine (mean dose 637 mg/day, mean treatment duration 80 days) and 21 to olanzapine (mean dose 16 mg/day, mean treatment duration 78 days). Quetiapine and olanzapine were similarly effective: in each treatment group significant improvements at Week 12 were observed for negative symptom scores on the SANS and the PANSS, and for subscale scores of affective flattening and alogia on the SANS. Both treatments were well tolerated in this patient population, with no worsening of extrapyramidal symptoms in either case. Anxiety and insomnia were the most common adverse events (> or =7% of patients in each group), but were not drug-related. Although this is a small study with limited power, the results support the effectiveness of quetiapine and olanzapine in treating the negative symptoms of schizophrenia.

show abstract

“…The authors suggested that the activation of prefrontal brain regions could be effective in improving blunted affect related symptoms (e.g. emotional withdrawal, social avoidance) [79]. Fahim and colleagues (2005) examined 12 schizophrenic patients with blunted affect before and after 22 weeks of treatment with quetiapine using passive viewing of emotionally negative stimuli.…”

Section: Processing Of Emotional Informationmentioning

confidence: 99%

Functional Magnetic Resonance Imaging and Treatment Strategies in Schizophrenia

Karch

Pogarell²,

Mulert³

2012

CPB

View full text Add to dashboard Cite

Neurobiological correlates of various treatment approaches (e.g. psychopharmacology, cognitive behavioural therapy) have become an important issue in recent neuroimaging studies. In schizophrenia, dysfunctions especially in frontal and parietal brain regions as well as the ventral striatum have been demonstrated in numerous studies. The review includes functional MRI studies about neurobiological correlates of treatment effects in schizophrenic patients. Treatment-associated changes in brain activity were shown especially in the anterior cingulate cortex, the dorsolateral prefrontal cortex, the ventral striatum and the amygdala. In addition, the differential effects of various treatment approaches including different neuroleptics (atypical neuroleptics, typical neuroleptics) as well as cognitive behavioural therapy will be considered in this review. The influence of functional differences on the differential effect of typical and atypical antipsychotics on cognitive functions will be discussed.

show abstract

Restoration of frontal activation during a treatment with quetiapine: an fMRI study of blunted affect in schizophrenia

Cited by 48 publications

References 24 publications

Regional Differences in the Action of Antipsychotic Drugs: Implications for Cognitive Effects in Schizophrenic Patients

Regional Differences in the Action of Antipsychotic Drugs: Implications for Cognitive Effects in Schizophrenic Patients

Quetiapine versus olanzapine for the treatment of negative symptoms in patients with schizophrenia

Functional Magnetic Resonance Imaging and Treatment Strategies in Schizophrenia

Contact Info

Product

Resources

About